Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival

BJU International

Volumn 114, Issue 6, 2014, Pages E70-E73

  Tait, Campbell ^b,c   Moore, David ^d   Hodgson, Clare ^d   Brown, Michael ^a   Morris, Thomas ^e   Growcott, Jim ^e   Malone, Michael ^e   Hughes, Andrew ^e   Renehan, Andrew ^d   Clarke, Noel W ^b,c   Dive, Caroline ^d  

^a Institute of Cancer Sciences   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

bone scintigraphy; CRPC; metastasis; prostate cancer; survival

Indexed keywords

PLACEBO; ZIBOTENTAN;

ADULT; AGED; ARTICLE; ASIAN; BLACK PERSON; BONE METASTASIS; BONE SCINTISCANNING; CASTRATION RESISTANT PROSTATE CANCER; CAUCASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; BONE TUMOR; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; SCINTISCANNING; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE;

EID: 84920148791     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12717     Document Type: Article

References (26)

1. Bubendorf L, Schopfer A, Wagner U, etal. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578-583
2. Carlin BI, Andriole GL,. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88: 2989-2994
3. Cooper CR, Chay CH, Gendernalik JD, etal. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003; 97: 739-747
4. Soloway MS, Hardeman SW, Hickey D, etal. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202
5. Clarke NW,. Management of the spectrum of hormone refractory prostate cancer. Eur Urol 2006; 50: 428-439
6. Fizazi K, Scher HI, Molina A, etal. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992
7. Scher HI, Fizazi K, Saad F, etal. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197
8. de Bono JS, Oudard S, Ozguroglu M, etal. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154
9. Higano CS, Schellhammer PF, Small EJ, etal. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-3679
10. Kantoff PW, Higano CS, Shore ND, etal. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422
11. Small EJ, Schellhammer PF, Higano CS, etal. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094
12. Smith MR, Saad F, Coleman R, etal. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46
13. Clarke NW, James ND, Mason MD, etal. Survival with newly diagnosed metastatic prostate cancer in the 'docetaxel era': data from >600 patients in the control arm of the STAMPEDE trial (NCT00268476). J Clin Oncol 2013; 31 (Suppl).): abstract 5012
14. Roy RR, Nathan BE, Beales JS, Chisholm GD,. 18 fluorine total body scans in patients with carcinoma of the prostate. Br J Urol 1971; 43: 58-64
15. Chisholm GD, Stone AR, Beynon LL, Merrick MV,. The bone scan as a tumour marker in prostatic carcinoma. Eur Urol 1982; 8: 257-260
16. Lecouvet FE, El Mouedden J, Collette L, etal. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 2012; 62: 68-75
17. Scher HI, Halabi S, Tannock I, etal. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159
18. Pollen JJ, Witztum KF, Ashburn WL,. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol 1984; 142: 773-776
19. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE,. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 2005; 65: 178-187
20. Imbriaco M, Larson SM, Yeung HW, etal. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res 1998; 4: 1765-1772
21. Sadik M, Hamadeh I, Nordblom P, etal. Computer-assisted interpretation of planar whole-body bone scans. J Nucl Med 2008; 49: 1958-1965
22. Ulmert D, Kaboteh R, Fox JJ, etal. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 2012; 62: 78-84
23. Nelson JB, Fizazi K, Miller K, etal. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 2012; 118: 5709-5718
24. Clarke NW,. The origin of the bone scan as a tumour marker in prostate cancer. Eur Urol 2006; 50: 873-878
25. Fox JJ, Morris MJ, Larson SM, Schoder H, Scher HI,. Developing imaging strategies for castration resistant prostate cancer. Acta Oncol 2011; 50 (Suppl. 1): 39-48
26. Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JB,. Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol 2012; 9: 376-385